# A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

> **NCT02610283** · PHASE2 · COMPLETED · sponsor: **Quark Pharmaceuticals** · enrollment: 341 (actual)

## Conditions studied

- Acute Kidney Injury

## Interventions

- **DRUG:** QPI-1002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02610283
- **Lead sponsor:** Quark Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2018-02
- **Final completion:** 2018-04
- **Target enrollment:** 341 (ACTUAL)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02610283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02610283, "A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02610283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*